Kalbe Farma stock trades at EUR 0.04 ahead of November 3 earnings

Published on 10/21/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kalbe Farma stock costs EUR 0.04 on October 21, 2026 ahead of November 3 earnings. First-half sales rose 14.00 percent year on year.

First-half growth and reporting date

Kalbe Farma announced first-half 2026 net sales growth of 14.00 percent on July 31, 2026.
Distribution and logistics revenue reached IDR 7.20 trillion in the first half of 2026, up 26.62 percent year on year.
Kalbe Farma stock trades at EUR 0.04 at 10:18 a.m. CEST at Lang & Schwarz on October 21, 2026.
Kalbe Farma is scheduled to report earnings on November 3, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma stock (ISIN ID1000125107) was trading at EUR 0.04 at Lang & Schwarz on October 21, 2026 at 10:18 a.m. CEST. The company is scheduled to publish its next earnings report on November 3, 2026, according to Investing.com.

First-half sales set the tone

Kalbe reported net sales growth of 14.00 percent for the first half of 2026 in its July 31, 2026 release. The figure covered prescription pharmaceuticals, consumer health, nutritionals, and distribution and logistics, while the company said higher raw material costs, currency depreciation, and product mix reduced gross, operating, and net profit margins, according to Kalbe Farma.

Distribution and logistics was the strongest reported growth engine. Kontan said the segment generated IDR 7.20 trillion in first-half 2026 revenue, up 26.62 percent from the prior year, while total revenue reached IDR 19.48 trillion, up 14.05 percent, in its September 29, 2026 analysis, according to Kontan.

What does the reporting date add?

The November 3 reporting date gives the next results release a clear test: whether double-digit sales growth can translate into firmer profitability after the margin pressure described in the first-half release. Investing.com lists the latest release as July 31, 2026 and shows an earnings-per-share result of IDR 19.81 against an IDR 19.07 forecast for that period.

Three dated company signals

On July 31, 2026, Kalbe announced 14.00 percent first-half net sales growth. On August 13, 2026, its EMOS digital-health business marked one decade of operations. On August 29, 2026, Kalbe held a precision-medicine and cell-therapy forum that brought together more than 200 physicians, researchers, academics, government representatives, and industry stakeholders, according to Kalbe Farma.

Next date for investors

The next substantiated company date is November 3, 2026, the scheduled earnings release listed by Investing.com.

Stock quote and valuation context

Kalbe Farma was trading at EUR 0.04 at Lang & Schwarz on October 21, 2026 at 10:18 a.m. CEST. On the Jakarta Stock Exchange, the stock was quoted at IDR 690.00 on October 21, 2026, with a 52-week range of IDR 630.00 to IDR 1,345.00 and market capitalization of IDR 31.2 trillion, according to the market data shown by Investing.com.

The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.